RT Journal Article
SR Electronic
T1 SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.04.01.021196
DO 10.1101/2020.04.01.021196
A1 Zhang, Qiang
A1 Zhang, Huajun
A1 Huang, Kun
A1 Yang, Yong
A1 Hui, Xianfeng
A1 Gao, Jindong
A1 He, Xinglin
A1 Li, Chengfei
A1 Gong, Wenxiao
A1 Zhang, Yufei
A1 Peng, Cheng
A1 Gao, Xiaoxiao
A1 Chen, Huanchun
A1 Zou, Zhong
A1 Shi, Zhengli
A1 Jin, Meilin
YR 2020
UL http://biorxiv.org/content/early/2020/04/03/2020.04.01.021196.abstract
AB Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, and rapidly spread worldwide. Previous studies suggested cat could be a potential susceptible animal of SARS-CoV-2. Here, we investigated the infection of SARS-CoV-2 in cats by detecting specific serum antibodies. A cohort of serum samples were collected from cats in Wuhan, including 102 sampled after COVID-19 outbreak, and 39 prior to the outbreak. 15 of 102 (14.7%) cat sera collected after the outbreak were positive for the receptor binding domain (RBD) of SARS-CoV-2 by indirect enzyme linked immunosorbent assay (ELISA). Among the positive samples, 11 had SARS-CoV-2 neutralizing antibodies with a titer ranging from 1/20 to 1/1080. No serological cross-reactivity was detected between the SARS-CoV-2 and type I or II feline infectious peritonitis virus (FIPV). Our data demonstrates that SARS-CoV-2 has infected cat population in Wuhan during the outbreak.